CLINICAL_TRIALS
trial_result
· 2016-11-01
Clinical Trial Update: Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. [Phase 3]
Summary
A Phase 3 trial evaluating nilotinib in adults with gastrointestinal stromal tumors resistant to imatinib and sunitinib has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED | Results posted: 2016-11-01